An immunomodulatory peptide derived from the thymus gland, approved in several countries for hepatitis B/C and studied for immune enhancement in cancer and infectious diseases.
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology|2015|Fu X et al.
OBJECTIVE: To explore the impact of triple anti-tumor therapy based on thymosin α1 (Tα1) combined with Huaier granule(HG) and sirolimus on the level of serum alpha-fetoprotein (AFP) in rat models of liver cancer. METHODS: Ninety Sprague-Dawley rats w…
Animal Study
PMID: 26062414
Biologicals : journal of the International Association of Biological Standardization|2015|Wang N et al.
Combined use of interferon (IFN) and thymosin (THY) holds a stronger antiviral effect than when applied individually because of their coordination and complementary action. In this study, prokaryotic expressed porcine IFNα1 (poIFNα1) or the porcine I…
Animal StudyIn Vitro
PMID: 26073788
Expert opinion on biological therapy|2015|Qiu S et al.
Hepatocellular carcinoma (HCC), the third leading cause of cancer-related death worldwide, is a disease of immune microenvironment. Chronic Hepatitis B virus (HBV) infection, also an immune-related disease, is the major etiological factor for HCC esp…
Randomized Controlled Trial
PMID: 26094695
Expert opinion on biological therapy|2015|Garaci E et al.
INTRODUCTION: Thymosin α1 (Tα1) is a naturally occurring polypeptide that regulates immune cell development and function, and is also capable of interacting with multiple target cells with relevant biological effects. The rationale of Tα1 use in canc…
ReviewAnimal Study
PMID: 26096345
Expert opinion on biological therapy|2015|Giacomini E et al.
OBJECTIVES: Thymosin α 1 (Tα1) recently gained interest as immune adjuvant for vaccines because of its ability to modulate the T-cell/dendritic cell (DC) axis and to improve antibody production. The objective of this study was to determine whether Tα…
In Vitro
PMID: 26096650
Expert opinion on biological therapy|2015|Serafino A et al.
BACKGROUND AND AIMS: The immunomodulatory activity of thymosin α1 (Tα1) on innate immunity has been extensively described, but its mechanism of action is not completely understood. We explored the possibility that Tα1-stimulation could affect the for…
In Vitro
PMID: 26098689
Expert opinion on biological therapy|2015|Camerini R, Garaci E
INTRODUCTION: Thymosin α 1 (Tα1) is a peptidic biological response modifier, which plays a significant role in activating and regulating various cells of the immune system. For the above-mentioned activities it is expected to exert a clinical benefit…
Review
PMID: 26098768
Expert opinion on biological therapy|2015|Moretti S et al.
Thymosin α1 (Tα1), an epithelial cell (EC)-derived cytokine, has the strong ability to modulate signals delivered through innate immune receptors on dendritic cells (DCs), thus instructing the initiation of appropriate immune responses to T cells. In…
PMID: 26098878
Biochemical and biophysical research communications|2015|Yuan C et al.
Thymosin α1 (Tα1) has been tested for cancer therapy for several years, in most cases, the anti-tumor effect of Tα1 was limited, especially when Tα1 was used as a single agent. The role of Tα1 in cancer treatment and the regulatory mechanisms by whic…
PMID: 26111447
Expert opinion on biological therapy|2015|Matteucci C et al.
BACKGROUND: Thymosin α-1 (Tα1) exploits a specific action on lymphoid cells and is able to induce in peripheral blood mononuclear cells (PBMCs) a strong transcriptional response. CD8 antiviral factor activity plays a role in the control or prevention…
In Vitro
PMID: 26094546
Molecular medicine reports|2015|Li X et al.
To determine the effect of thymosin α1 (Tα1) on the phenotypic and functional maturation of HL‑60 cells, freeze‑thaw antigen‑loaded dendritic cells (DCs) were derived from peripheral blood mononuclear cells (PBMCs) of children with acute lymphoblasti…
PMID: 26239360
Immunopharmacology and immunotoxicology|2015|Jia Z et al.
CONTEXT: Thymosin α1 (Tα1) is considered to be a promising immunomodulatory drug and could balance immunity and tolerance in immune tolerance and autoimmunity. OBJECTIVE: To explore the efficacy of Tα1 plus routine complex treatment in patients with…
Randomized Controlled Trial
PMID: 26250523
Apoptosis : an international journal on programmed cell death|2015|Lao X et al.
Thymosin alpha 1 (Tα1) is commonly used for treating several diseases; however its usage has been limited because of poor penetration of the target tissue, such as tumor cells. In the present study, Tα1-iRGD, a peptide by conjugating Tα1 with the iRG…
Animal StudyIn Vitro
PMID: 26283169
Cancer immunology, immunotherapy : CII|2015|Binsfeld M et al.
Multiple myeloma (MM) is characterized by the accumulation of monoclonal plasma cells in the bone marrow and causes several immune alterations in patients. Thymosin α1 (Tα1) is a thymic peptide that has been associated with immuno-stimulating propert…
Animal StudyIn Vitro
PMID: 25971542
Molecular medicine reports|2015|Wang X et al.
The present study aimed to investigate the effects of treatment with thymosin α1 (TA1) or interferon α (IFNα) following the establishment of severe acute pancreatitis (SAP) in rats. A total of 144 Sprague‑Dawley rats were randomly divided into four g…
Animal Study
PMID: 26330363
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine|2015|Xiao Q et al.
OBJECTIVE: To study the effect of acupuncture on the immune function of sepsis patients. METHODS: Ninety sepsis patients were assigned to the control group, the thymosin a1 group, and the acupuncture treatment group according to random digit table, 3…
Randomized Controlled Trial
PMID: 26380438
Clinical laboratory|2015|Li Y, Li C
BACKGROUND: To explore the role of human immunoglobulin (Ig) and thymosin α1 therapy for severe sepsis through comparison between bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy group (A group) and bundles group (B group). MET…
PMID: 26427133
Expert opinion on biological therapy|2015|Nepravishta R et al.
OBJECTIVE: Thymosin α1 (Tα1) is a peptide hormone whose therapeutic application has been approved in several diseases, but the description of a precise receptor for its therapeutic action still remains elusive and some knowledge of the mechanism of i…
PMID: 25642593
International immunopharmacology|2015|Han D et al.
OBJECTIVE: This meta-analysis was performed to evaluate the efficacy of ulinastatin (UTI) and thymosin α1 (Tα1) based immunomodulatory strategy in sepsis patients. METHODS: A systematic search was made of MEDLINE, Cochrane, ISI Web of Science and SCO…
ReviewMeta-Analysis
PMID: 26522590
International journal of clinical and experimental medicine|2015|Zhang D, Zhou Y, Cheng Q
This study is to investigate the effects of the thymosin α1 (Tα1) and hydrocortisone (HC) combination treatment on the immune responses in septic mice. According to different treatments, mice were divided into the control group (n = 18), the sepsis m…
Animal Study
PMID: 26550219